Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...

EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...

Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 cents ...

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q4 earnings results on Wednesday, March 12th, after market close. The consensus EPS Estimate is -$0.20 (+9.1% Y/Y) and the consensus Revenue ...

Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned a consensus rating of “Buy” from the six analysts ...